What Has Been the Progress and Growth of the Dengue Vaccine Market in Recent Years?
The dengue vaccine market has seen considerable growth due to a variety of factors.
• In recent times, the dengue vaccine market has experienced swift growth. The market size is projected to rise from $0.64 billion in 2024 to $0.72 billion in 2025, indicating a compound annual growth rate (CAGR) of 12.4%.
The remarkable growth recorded in the past period is associated with factors such as increased travel and urbanization, a surge in demand for efficient vaccines, growing exposure to foreign travel, enhanced healthcare services, and a rise in mass vaccination drives.
What Can Be Expected from the Dengue Vaccine Market Size?
The dengue vaccine market is expected to maintain its strong growth trajectory in upcoming years.
• In the upcoming years, the dengue vaccine market is anticipated to undergo substantial expansion. The projection suggests that by 2029, the market will have reached $1.14 billion, demonstrating a compound annual growth rate (CAGR) of 12.3%.
This escalation during the forecasted timeframe is a result of the surge in dengue cases, heightened efforts by various organizations, an increase in clinical trials, and a growing focus on multi-strain and tetravalent vaccine formulations. The forecast period is also set to witness trends like a rising demand for preventative vaccines, advancements in vaccine technology, the development of combination vaccines, an increase in research and clinical trials for potential vaccine candidates, plus an emphasis on enhancing vaccine efficacy and safety profiles.
What Are the Critical Driver Fuelling The Dengue Vaccine Market's Growth?
The burgeoning incidence of dengue fever is anticipated to fuel the expansion of the dengue vaccine markets in the future. Dengue fever is a mosquito-borne viral infection propagated by Aedes aegypti mosquitoes, which results in high fever, migraines, joint discomfort, and skin irritations. The uptick in dengue fever cases is attributed to factors like climate change, urbanization, ineffective mosquito control, and evolution of the virus. The dengue vaccine operates by invigorating the immune system to detect and fight the dengue virus, diminishing the severity of the infection and cutting down the possibility of serious health implications, while concurrently lowering the number of cases and hospital admissions. To illustrate, data from the World Health Organization, an intergovernmental organization based in Switzerland, recorded over 7 million dengue cases in the American region in April 2024, a sharp increase from the 4.6 million cases reported in 2023. Consequently, the escalating incidence of dengue fever is catalyzing the expansion of the dengue vaccine market.
How Is The Dengue Vaccine Market segmented?
The dengue vaccinemarket covered in this report is segmented –
1) By Type: Live Attenuated Vaccine, Chimeric Live Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccine, Nucleic Acid Based Vaccine
2) By Vaccine Phase: Phase I, Phase II, Phase III
3) By Treatment: Diuretic, Anti-Allergic, Blood Thinners, Other Treatments
4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
5) By End-User: Hospitals, Clinics, Government Institutes, Non-Governmental Organizations, Other End-Users
Subsegments:
1) By Live Attenuated Vaccine: Single Strain, Multi-Strain
2) By Chimeric Live Attenuated Vaccine: Tetravalent Chimeric Vaccine, Monovalent Chimeric Vaccine
3) By Inactivated Vaccine: Whole Virus Inactivated Vaccine, Split Virus Vaccine
4) By Subunit Vaccine: Recombinant Protein Vaccine, Peptide-Based Vaccine
5) By Nucleic Acid Based Vaccine: DNA Vaccine, mRNA Vaccine
Pre-Book The Dengue Vaccine Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Dengue Vaccine Market?
Leading enterprises in the dengue vaccine market are centering their efforts on the invention of novel vaccine formulations like the dengue tetravalent vaccine. This type of vaccine is designed to provide defense against all four serotypes of dengue virus in just one formulation. The dengue tetravalent vaccine enables immunity from all four dengue virus serotypes (DEN-1, DEN-2, DEN-3, and DEN-4), giving thorough protection from dengue fever. For instance, Takeda Pharmaceutical Company, based in Japan, gained approval for their QDENGA vaccine from the European Commission (EC) in December 2022. This vaccine is meant for individuals aged 4 years and above and is a live-attenuated vaccine that has been adopted in several nations where dengue is endemic for protection against dengue fever. The QDENGA vaccine is based on a weakened dengue serotype two virus acting as the genetic base for the other three serotypes. It is administered in two 0.5 mL doses within 0 and 3 months and specifically targets those aged four years and beyond. Its efficacy against dengue is around 80.2% as shown in a Phase 3 trial, showing more promising in preventing hospitalizations. The vaccine affords protection lasting roughly 4.5 years, which is longer than many other vaccines.
Who Are the Key Players In The Dengue Vaccine Market?
Major companies operating in the dengue vaccine market are:
• Merck & Co. Inc.
• Sanofi Pasteur Limited
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company
• Sun Pharmaceutical Industries Ltd.
• Biological E. Limited
• Saint Louis University
• Indian Immunologicals Limited
• Serum Institute of India Pvt. Ltd.
• Bavarian Nordic
• Instituto Butantan
• Bharat Biotech Ltd.
• Panacea Biotec Limited
• SABIN Vaccine Institute
• Medigen Vaccine Biologics Corporation
• Emergex Vaccines Holding Ltd.
• BioNet-Asia Co. Ltd.
• Codagenix Inc.
• KM Biologics Co. Ltd.
• Chula Vaccine Research Center
• Imutex Ltd.
What Is The Most Dominant Region In The Dengue Vaccine Market?
Asia-Pacific was the largest region in the dengue vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the dengue vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
